Table 2.
Acute symptoms observed during the intervention period.
| Placebo (n = 48) | LF (n = 53) | RD (95% CI) | p | |
|---|---|---|---|---|
| GASTROINTESTINAL SYMPTOM | ||||
| Prevalence, n (%) | 30 (62.5) | 22 (41.5) | 0.21 (0.019, 0.401) | 0.046 |
| Total days | 1 (0, 3) | 0 (0, 2.5) | 0.151 | |
| Duration, days/episode | 1 (1, 2) | 2 (1.38, 3) | 0.060 | |
| Medication, n (%) | 12 (40) | 13 (59.1) | 0.262 | |
| RESPIRATORY SYMPTOM | ||||
| Prevalence, n (%) | 47 (97.9) | 47 (88.7) | 0.092 (−0.002, 0.187) | 0.115 |
| Total days | 15 (6.25, 22.75) | 9 (3.5, 18.5) | 0.030 | |
| Duration, days/episode | 5 (2.75, 6.33) | 4 (2.33, 5.5) | 0.194 | |
| Medication, n (%) | 38 (80.9) | 37 (78.7) | 1.000 | |
RD, risk difference; CI, confidence interval.
Values represent the number (%) or the median (interquartile range).
Prevalence is defined as the number of participants who experienced more than one symptom.
Total days is defined as the cumulative number of symptomatic days.
Duration is defined as the mean of consecutive days per episode.
Risk difference is calculated by subtracting the prevalence in the LF group from the prevalence in the placebo group.